| Name | T-1095 |
|---|---|
| Synonyms |
SGLT1,Sodium-dendent glucose cotransporters,T 1095,antidiabetic,SGLT2,Inhibitor,,orally active,SGLT,inhibit
MFCD28404653 T1095 T1095 T-1095, 10 mM in DMSO [(2R,3S,4S,5R,6S)-6-{2-[3-(1-benzofuran-5-yl)propanoyl]-3-hydroxy-5-methylphenoxy}-3,4,5-trihydroxyoxan-2-yl]methyl methyl cbonate 2-[3-(1-Benzofuran-5-yl)propanoyl]-3-hydroxy-5-methylphenyl 6-O-(methoxycarbonyl)-β-D-glucopyranoside ; T1095 1-Propanone, 3-(5-benzofuranyl)-1-[2-hydroxy-6-[[6-O-(methoxycbonyl)-β-D-glucopyranosyl]oxy]-4-methylphenyl] ((2r,3s,4s,5r,6s)-6-(2-(3-(benzofuran-5-yl)propanoyl)-3-hydroxy-5-methylphenoxy)-3,4,5-trihydroxytetrahydro-2h-pyran-2-yl)methyl methyl cbonate |
| Description | T-1095 is a selective and orally active Na+-glucose cotransporter (SGLT) inhibitor with IC50s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research[1]. |
|---|---|
| Related Catalog | |
| Target |
hSGLT1:22.8 μM (IC50) hSGLT2:2.3 μM (IC50) |
| In Vivo | T-1095 is absorbed into the circulation via oral administration, is metabolized to the active form, T-1095A, and suppresses the activity of SGLTs in the kidney[1]. Orally administered T-1095 (3-30 mg/kg) increases urinary glucose excretion in diabetic animals, thereby decreasing blood glucose levels[1]. With long-term T-1095 (0.01% or 0.1% T-1095 mixed diet; for 28 days) treatment, both blood glucose and HbA1c levels were reduced in streptozotocin (STZ)-induced diabetic rats and yellow KK mice. In addition, there was amelioration of abnormal carbohydrate metabolism, i.e., hyperinsulinemia and hypertriglyceridemia, and of the development of microalbuminuria, in yellow KK mice[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 732.3±60.0 °C at 760 mmHg |
| Molecular Formula | C26H28O11 |
| Molecular Weight | 516.49 |
| Flash Point | 396.7±32.9 °C |
| Exact Mass | 516.163147 |
| LogP | 4.43 |
| Vapour Pressure | 0.0±2.5 mmHg at 25°C |
| Index of Refraction | 1.632 |